TCR-engineered adoptive cell therapy effectively treats intracranial murine glioblastoma
Journal for ImmunoTherapy of Cancer · 2023-02 · 11 (2) · e006121
DOI: 10.1136/jitc-2022-006121 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 20.02.2023. Verfasst von Maximilian O Schaettler und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurological Surgery, Washington University School of Medicine, St. Louis, Missouri, USA. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Glioblastoma. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NIAID NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
Background
Adoptive cellular therapies with chimeric antigen receptor T cells have revolutionized the treatment of some malignancies but have shown limited efficacy in solid tumors such as glioblastoma and face a scarcity of safe therapeutic targets. As an alternative, T cell receptor (TCR)–engineered cellular therapy against tumor-specific neoantigens has generated significant excitement, but there exist no preclinical systems to rigorously model this approach in glioblastoma.
Methods
We employed single-cell PCR to isolate a TCR specific for the Imp3 D81N neoantigen (mImp3) previously identified within the murine glioblastoma model GL261. This TCR was used to generate the Mutant Imp3-Specific TCR TransgenIC (MISTIC) mouse in which all CD8 T cells are specific for mImp3. The therapeutic efficacy of neoantigen-specific T cells was assessed through a model of cellular therapy consisting of the transfer of activated MISTIC T cells and interleukin 2 into lymphodepleted tumor-bearing mice. We employed flow cytometry, single-cell RNA sequencing, and whole-exome and RNA sequencing to examine the factors underlying treatment response.
Results
We isolated and characterized the 3×1.1C TCR that displayed a high affinity for mImp3 but no wild-type cross-reactivity. To provide a source of mImp3-specific T cells, we generated the MISTIC mouse. In a model of adoptive cellular therapy, the infusion of activated MISTIC T cells resulted in rapid intratumoral infiltration and profound antitumor effects with long-term cures in a majority of GL261-bearing mice. The subset of mice that did not respond to the adoptive cell therapy showed evidence of retained neoantigen expression but intratumoral MISTIC T cell dysfunction. The efficacy of MISTIC T cell therapy was lost in mice bearing a tumor with heterogeneous mImp3 expression, showcasing the barriers to targeted therapy in polyclonal human tumors.
Conclusions
We generated and characterized the first TCR transgenic against an endogenous neoantigen within a preclinical glioma model and demonstrated the therapeutic potential of adoptively transferred neoantigen-specific T cells. The MISTIC mouse provides a powerful novel platform for basic and translational studies of antitumor T-cell responses in glioblastoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurological Surgery, Washington University School of Medicine, St. Louis, Missouri, USA.
- Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
- Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
- Department of Neurosurgery, Johns Hopkins University, Baltimore, Maryland, USA.
- Department of Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts, USA.
- Bursky Center for Human Immunology & Immunotherapy Programs, Washington University School of Medicine, St. Louis, Missouri, USA.
ORCID-Profile: Rupen Desai, Gavin P Dunn
Förderung
- NCI NIH HHS
- NIAID NIH HHS
- NIGMS NIH HHS
- National Institutes of Health
- Cancer Research Institute
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Schaettler, M. O., Desai, R., Wang, A. Z., Livingstone, A. J., Kobayashi, D. K., Coxon, A. T., Bowman-Kirigin, J. A., Liu, C. J., Li, M., Bender, D. E., White, M. J., Kranz, D. M., Johanns, T. M., & Dunn, G. P. (2023). TCR-engineered adoptive cell therapy effectively treats intracranial murine glioblastoma. Journal for ImmunoTherapy of Cancer, 11(2), e006121. https://doi.org/10.1136/jitc-2022-006121
Vancouver
Schaettler MO, Desai R, Wang AZ, Livingstone AJ, Kobayashi DK, Coxon AT, et al. TCR-engineered adoptive cell therapy effectively treats intracranial murine glioblastoma. Journal for ImmunoTherapy of Cancer. 2023;11(2):e006121. doi:10.1136/jitc-2022-006121
BibTeX
@article{Schaettler2023,
author = {Schaettler, Maximilian O and Desai, Rupen and Wang, Anthony Z and Livingstone, Alexandra J and Kobayashi, Dale K and Coxon, Andrew T and Bowman-Kirigin, Jay A and Liu, Connor J and Li, Mao and Bender, Diane E and White, Michael J and Kranz, David M and Johanns, Tanner M and Dunn, Gavin P},
title = {TCR-engineered adoptive cell therapy effectively treats intracranial murine glioblastoma},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2023},
volume = {11},
number = {2},
pages = {e006121},
doi = {10.1136/jitc-2022-006121}
}
EUVIMED